Blood–brain barrier penetrant PARP inhibitors may be effective in glioma patients carrying GVs in ATM, BRCA2, BRIP1, FANCA, and SDHA identified here that are associated with HRR deficiency, and may act synergistically with radio-, chemo-, and immunotherapy [70]. Here, FANCA is linked to central nervous system cancer.